Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 86
- 主要终点
- Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor
研究概览
简要总结
Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 15 Years 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age (15-50 years)
- •Both genders
- •Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)
排除标准
- •Pt with history of antifungals in last one month
- •Pt on immunosuppressants or steroid therapy
- •Pregnant and lactating women
- •Pt with chronic medical conditions ( Diabetes and hypertension)
研究组 & 干预措施
1% Clotrimazole
topical 1 % clotrimazole twice daily for 2 weeks
干预措施: Topical 1 % clotrimazole twice daily 2 weeks (Drug)
Itraconazole
Oral itraconazole 200mg daily 5 days
干预措施: Oral itraconazole 200mg daily for 5 days (Drug)
结局指标
主要结局
Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor
时间窗: 3 months
Data analysis will be performed using SPSS version 20. The quantitative variable (age, BMI and duration of PV) will be presented as mean ± standard deviation (SD) or median interquartile range (IQR) after checking normality of data by using Shapiro-Wilk test. Frequency and percentages will be used for categorical variables (gender, severity of PV, area of residence, level of education and efficacy). Efficacy will be compared between groups using Chi-square or Fisher exact test. Efficacy will be stratified by age, gender, BMI, duration of PV and severity of PV to deal with effect modifiers. Post-stratification chi-square test or Fischer exact test will be used as test of significance. A p-value of ≤ 0.05 will be considered statistically significant.
次要结局
未报告次要终点
研究者
Zaeema Aman
Resisent Dermatology
Combined Military Hospital Abbottabad